[go: up one dir, main page]

AR078674A1 - Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas - Google Patents

Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas

Info

Publication number
AR078674A1
AR078674A1 ARP100103812A ARP100103812A AR078674A1 AR 078674 A1 AR078674 A1 AR 078674A1 AR P100103812 A ARP100103812 A AR P100103812A AR P100103812 A ARP100103812 A AR P100103812A AR 078674 A1 AR078674 A1 AR 078674A1
Authority
AR
Argentina
Prior art keywords
alkyl
3alkyl
hydrogen
nr6r7
alkoxy
Prior art date
Application number
ARP100103812A
Other languages
English (en)
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078674(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of AR078674A1 publication Critical patent/AR078674A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones farmacéuticas que los comprenden y al uso de los compuestos y sus composiciones en tratamiento, por ejemplo, en el tratamiento de enfermedades inflamatorias, en particular enfermedad inflamatoria respiratoria. También se provee un intermediario de la preparacion de dichos compuestos. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 es H, una cadena de alquilo C1-15 ramificada o no ramificada, saturada o insaturada, en donde opcionalmente uno o varios carbonos (por ejemplo, 1, 2 o 3 carbonos, apropiadamente 1 o 2, en particular 1) están reemplazados por un heteroátomo seleccionado de O, N, S(O)p (por ejemplo, un grupo CH2 está reemplazado con O o con NH o con S o con SO2 o un grupo -CH3 en el término de la cadena o en una ramificacion está reemplazado con OH o con NH2), en donde dicha cadena está opcionalmente sustituida con uno o varios grupos (por ejemplo, 1 a 3, tales como 2 grupos) seleccionados, de modo independiente, de oxo, halogeno, un grupo arilo, heteroarilo, carbociclilo o un grupo heterociclilo, cada grupo arilo, heteroarilo, carbociclilo o heterociclilo que lleva 0 a 3 sustituyentes seleccionados de halogeno, -hidroxilo, -alquilo C1-6, -alcoxi C1-6, -alcoxi C2-3-Oalquilo C1-3, -alquil C2-3-Oalquilo C1-3, - hidroxialquilo C1-3, -haloalquilo C1-6, amino, -monoalquil C1-4 o dialquil C2-8-amino, -monoacil C1-4 o -diacil C2-8-amino, -alquil C0-6-S(O)palquilo C1-6, -alquil C0-6-S(O)pNR6R7, -alquil C0-6-NR8alquil C0-6-S(O)palquilo C1-6, -alquil C0-6-C(O)Oalquilo C0-6, -NR8alquil C0-6-C(O)NR6R7-NR8alquil C0-6-C(O)alquilo C0-6, -alquil C0-6-C(O)NR6R7 y -alquil C0-6-C(O)alquilo C1-6; y/o un arilo heterociclilo o carbociclilo; X es arilo C6-10 o un heteroarilo C5-9 sustituido cada uno con R2a y bi R2b en donde R2a está seleccionado de hidrogeno, -alquilo C1-3, halo, hidroxilo, ciano, -haloalquilo C1-3, -alcoxi C1-3, -alcoxi C2-3-Oalquilo C1-3, -alquil C2-3-Oalquilo C1-3, -hidroxialquilo C1-3, -alquil C0-6-S(O)qalquilo C1-3, -alquil C0-6-S(O)NR6R7, -alquil C0-6-NR8alquil C0-6-S(O)palquilo C1-6, -alquil C0-6-C(O)OH, -alquil C0-6-C(O)Oalquilo C1-6, -NR8alquil C0-6-C(O)NR6R7, -NR8aIquil C0-6-C(O)alquilo C1-6, -alquil C0-6-C(O)NR6R7 y -alquil C0-6-C(O)aIquilo C1-6; y R2b está seleccionado de hidrogeno, alquilo C1-3, halo, hidroxilo, ciano, -haloalquilo C1-3, -alcoxi C1-3 y -alquil C0-6-S(O)qaIquilo C1-3; R3a es hidroxilo; R3b está seleccionado de hidrogeno, hidroxilo, halo, ciano, -haloalquilo C1-3, -hidroxialquilo C1-3, -alcoxi C1-3 y -S(O)qalquilo C1-3; R4 es hidrogeno o -alquilo C1-3; R5 es hidrogeno o -alquilo C1-3; R6 es hidrogeno o -alquilo C1-6; R7 es hidrogeno o -alquilo C1-6; R8 es hidrogeno o -alquilo C1-6; p es 0 o un numero entero 1 o 2; q es 0 o un numero entero 1 o 2 o una de sus sales farmacéuticamente aceptables, incluyendo todos sus estereoisomeros, tautomeros y derivados isotopicos. Reivindicacion 22: Un intermediario de la formula (6).
ARP100103812A 2009-10-19 2010-10-19 Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas AR078674A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0918249.4A GB0918249D0 (en) 2009-10-19 2009-10-19 Compounds

Publications (1)

Publication Number Publication Date
AR078674A1 true AR078674A1 (es) 2011-11-23

Family

ID=41462531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103812A AR078674A1 (es) 2009-10-19 2010-10-19 Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas

Country Status (36)

Country Link
US (4) US8741909B2 (es)
EP (1) EP2491037B1 (es)
JP (1) JP5889792B2 (es)
KR (1) KR101770616B1 (es)
CN (1) CN102712645B (es)
AR (1) AR078674A1 (es)
AU (1) AU2010309832B2 (es)
BR (1) BR112012009214A2 (es)
CA (1) CA2777902C (es)
CL (1) CL2012000981A1 (es)
CR (1) CR20120264A (es)
CY (1) CY1116057T1 (es)
DK (1) DK2491037T3 (es)
EA (1) EA020330B3 (es)
EC (1) ECSP12011805A (es)
ES (1) ES2477270T3 (es)
GB (1) GB0918249D0 (es)
HK (1) HK1173728A1 (es)
HR (1) HRP20140599T1 (es)
IL (1) IL219248A (es)
ME (1) ME02064B (es)
MX (1) MX2012004525A (es)
MY (1) MY164731A (es)
NI (2) NI201200061A (es)
NZ (2) NZ599162A (es)
PE (1) PE20121390A1 (es)
PH (1) PH12012500620A1 (es)
PL (1) PL2491037T3 (es)
PT (1) PT2491037E (es)
RS (1) RS53385B (es)
SI (1) SI2491037T1 (es)
SM (1) SMT201400086B (es)
TW (1) TWI478923B (es)
UA (1) UA108743C2 (es)
WO (1) WO2011048111A1 (es)
ZA (1) ZA201203662B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
BR112012018415A2 (pt) 2010-02-01 2020-08-04 Cancer Research Technology Limited composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto.
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MX351530B (es) 2011-12-15 2017-10-18 Novartis Ag Uso de inhibidores de la actividad o fundicion de la pi3k.
ES2650791T3 (es) * 2012-03-13 2018-01-22 Respivert Limited Estabilización de composiciones farmacéuticas
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
TW201522341A (zh) * 2013-03-15 2015-06-16 Respivert Ltd 化合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
US11173186B2 (en) 2013-06-14 2021-11-16 Psioxus Therapeutics Limited Dosing regime and formulations for type B adenovirus
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
PE20170640A1 (es) 2014-07-04 2017-05-26 Lupin Ltd Derivados de quinolizinona como inhibidores de pi3k
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3740468A4 (en) 2018-01-20 2021-10-06 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
CN108516976B (zh) * 2018-04-27 2020-07-03 四川大学华西医院 一种7-脱氮嘌呤衍生物及其四元环超分子结构
WO2020058072A1 (en) * 2018-09-18 2020-03-26 Société des Produits Nestlé S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
ES2192866T3 (es) 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
CA2369895C (en) 1999-01-11 2010-12-21 Princeton University High affinity inhibitors for target validation and uses thereof
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PT3029041T (pt) 2000-04-25 2020-05-13 Icos Corp Inibidores de fosfatidil-inositol 3-quinase delta humana
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1578898A2 (en) 2001-07-13 2005-09-28 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
EP1553947A4 (en) 2002-10-21 2006-11-29 Bristol Myers Squibb Co QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
WO2004089988A2 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
US20100267778A1 (en) 2003-08-04 2010-10-21 Shinya Kusuda Diphenyl ether compound, process for producing the same, and use
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
ME02688B (me) * 2004-05-13 2017-10-20 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
JP2008501707A (ja) 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
CN101775013A (zh) 2004-09-13 2010-07-14 小野药品工业株式会社 含氮杂环衍生物及含有其作为活性成分的药物
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006089106A2 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
DK2004654T3 (da) 2006-04-04 2013-07-22 Univ California Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
WO2007134876A2 (en) 2006-05-24 2007-11-29 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
JP2009542662A (ja) 2006-06-29 2009-12-03 シェーリング コーポレイション 置換二環系および置換三環系トロンビン受容体アンタゴニスト
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US8362066B2 (en) 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
PE20090215A1 (es) * 2007-05-09 2009-03-30 Novartis Ag Compuestos derivados de imidazopiridazinas como inhibidores de cinasa
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
KR101897881B1 (ko) * 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
WO2010065923A2 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
JP2013501008A (ja) 2009-08-05 2013-01-10 バーシテック リミテッド 抗ウイルス性化合物ならびにそれを含む医薬組成物
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
KR20140005150A (ko) 2010-09-30 2014-01-14 키에시 파르마슈티시 엣스. 피. 에이. 흡입용 건조 분말 제제 내 마그네슘 스테아레이트의 용도
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ES2650791T3 (es) 2012-03-13 2018-01-22 Respivert Limited Estabilización de composiciones farmacéuticas

Also Published As

Publication number Publication date
CL2012000981A1 (es) 2012-08-31
EA020330B3 (ru) 2015-07-30
NZ609147A (en) 2014-03-28
MY164731A (en) 2018-01-30
CN102712645B (zh) 2015-10-21
MX2012004525A (es) 2012-05-29
CA2777902A1 (en) 2011-04-28
PT2491037E (pt) 2014-07-11
RS53385B (en) 2014-10-31
IL219248A (en) 2015-02-26
JP5889792B2 (ja) 2016-03-22
ES2477270T3 (es) 2014-07-16
PH12012500620A1 (en) 2015-03-20
TW201124418A (en) 2011-07-16
PE20121390A1 (es) 2012-10-15
US8741909B2 (en) 2014-06-03
ME02064B (me) 2015-05-20
US20120208799A1 (en) 2012-08-16
NI201200061A (es) 2013-05-15
TWI478923B (zh) 2015-04-01
EA201270575A1 (ru) 2012-09-28
HRP20140599T1 (hr) 2014-09-12
IL219248A0 (en) 2012-06-28
PL2491037T3 (pl) 2014-09-30
US20160264583A1 (en) 2016-09-15
CR20120264A (es) 2013-01-25
US20180118754A1 (en) 2018-05-03
AU2010309832A1 (en) 2012-04-19
AU2010309832B2 (en) 2014-01-30
HK1173728A1 (en) 2013-05-24
ZA201203662B (en) 2013-10-30
CA2777902C (en) 2018-03-06
EP2491037A1 (en) 2012-08-29
NI201300035A (es) 2013-06-04
US20140249164A1 (en) 2014-09-04
UA108743C2 (uk) 2015-06-10
ECSP12011805A (es) 2012-06-29
EA020330B1 (ru) 2014-10-30
SI2491037T1 (sl) 2014-08-29
KR20120114225A (ko) 2012-10-16
BR112012009214A2 (pt) 2016-08-16
CY1116057T1 (el) 2017-02-08
CN102712645A (zh) 2012-10-03
NZ599162A (en) 2013-08-30
GB0918249D0 (en) 2009-12-02
DK2491037T3 (da) 2014-07-21
JP2013508334A (ja) 2013-03-07
WO2011048111A1 (en) 2011-04-28
US9321773B2 (en) 2016-04-26
KR101770616B1 (ko) 2017-08-23
SMT201400086B (it) 2014-09-08
EP2491037B1 (en) 2014-04-30
US9834560B2 (en) 2017-12-05

Similar Documents

Publication Publication Date Title
AR078674A1 (es) Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas
AR081638A1 (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del vih
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CL2015001304A1 (es) Compuestos derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CY1116958T1 (el) Υποκατεστημενες τριαζολοπυριδινες και η χρηση τους ως ττκ αναστολεις
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX380619B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
AR038404A1 (es) Derivados de nicotinamida utiles como inhibidores de pde4, procedimiento para la preparacion del compuesto y composicion farmaceutica que lo incluye
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
CL2015001319A1 (es) Compuestos derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y metodo para la preparacion de compuestos.
AR078722A1 (es) Derivados de 2-oxo-1-pirrolidinila imidazotiadiazol
AR116001A2 (es) Composición farmacéutica 271
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP088257A (es) Derivados de amida
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
UY29485A1 (es) Esteres alquílicos de aminoalcoholes cíclicos, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
UY30673A1 (es) Derivados 6, 7 y 8 sustituidos del acido (3r)-5-oxo-2,3-dihidro-5h-tiazolo[3,2a]piridin-3-carboxilico, composiciones farmacéuticas conteniéndolos y aplicaciones.

Legal Events

Date Code Title Description
FB Suspension of granting procedure